KalVista Pharmaceuticals(KALV) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

BofA Securities Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $22
Moomoo NewsMar 18 02:33 ET · Ratings
Buy Rating for KalVista Pharmaceuticals: Strong Regulatory Progress and Market Potential for Sebetralstat
TipRanksMar 17 02:15 ET · Ratings
H.C. Wainwright Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20
Moomoo NewsMar 15 02:31 ET · Ratings
KalVista Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow JonesMar 14 08:41 ET · Ratings
JonesTrading Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Cuts Target Price to $30
Moomoo NewsMar 14 02:32 ET · Ratings
Needham Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $28
Moomoo NewsMar 13 02:32 ET · Ratings

Comments

Teddy123

Mar 12 19:16

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

$KalVista Pharmaceuticals (KALV.US)$
KalVista's Oral HAE Treatment Delivers 76-Minute Relief as FDA Review Nears

Teddy123

Mar 3 20:05

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

$KalVista Pharmaceuticals (KALV.US)$
Revolutionary Oral HAE Treatment From KalVista Achieves 96% Effectiveness in Minutes

Teddy123

Feb 10 20:15

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

$KalVista Pharmaceuticals (KALV.US)$
Critical HAE Treatment Breakthrough: KALV's Sebetralstat Delivers Relief in 78 Minutes While Current Therapies Fall Short

1

74425369

Feb 4 22:08

$KalVista Pharmaceuticals (KALV.US)$ saw significant insider activity this week. On February 3, major shareholder Venrock Healthcare Capital Partners purchased 14,562 shares at $9.22/share ($134K total), increasing its stake to 5M+ shares (46% ownership). This follows Venrock’s 43,707-share purchase on January 30 at ~$9.20/share ($402K).
The buying spree aligns with key developments:
🔹 February 3: Granted 261,000 stock options to 52 new hires to drive growth
🔹 June 17, 2025: FDA decision deadlin...

1

MARKET-TEST-DUMMY

Sep 29, 2024 05:37

👀

$KalVista Pharmaceuticals (KALV.US)$

KALV KalVista Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Market Insights